Regulus Therapeutics Inc.
RGLS
Rang in aandelen
#17275
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Aandeelprijs
$8.16
Laatst gesynchroniseerd: 2025-06-26
Marktkapitalisatie
$234.57M
Verandering (1 dag)
0.00%
Verandering (1 jaar)
-88.86%
Land
US
Handel Regulus Therapeutics Inc. (RGLS)
Categorie
Healthcare
Koersgeschiedenis voor Regulus Therapeutics Inc. (RGLS)
Hoogste slotkoers: $73.27 op 2024-11-01
Laagste slotkoers: $21.00 op 2010-04-01
Laagste slotkoers: $21.00 op 2010-04-01
Koersgeschiedenis van Regulus Therapeutics Inc. van 2010 tot 2026
Jaarlijkse koersprestatie
| Jaar | Prestaties |
|---|---|
| 2024 | 113.53% |
| 2023 | 140.97% |
| 2022 | -61.38% |
| 2021 | -67.58% |
| 2020 | -13.91% |
| 2019 | 22.71% |
| 2018 | 12.94% |
| 2017 | 104.37% |
| 2016 | -25.20% |
| 2015 | -38.37% |
| 2014 | 34.13% |
| 2013 | 93.41% |
| 2012 | 67.05% |
| 2011 | 2.83% |
| 2010 | 0.00% |
Aandelenkoers van vergelijkbare bedrijven of concurrenten
| Bedrijf | Aandelenkoers | Verandering 1jr% | Land |
|---|---|---|---|
| $527.18 | 23.67% |
US
|
|
| $251.29 | 814.11% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $890.85 | 6.72% |
NL
|
|
| $752.87 | 7.40% |
CH
|
